AI Article Synopsis
- Lung cancer is the top cause of cancer-related deaths in both the US and worldwide, but mortality rates are decreasing thanks to better treatments and lower incidence rates.
- Recent advancements in targeted therapies and immunotherapy have improved patient outcomes but have also made treatment options more complicated for healthcare providers.
- A conference, "Bridging the Gaps in Lung Cancer," was held to address knowledge gaps and controversies regarding lung cancer diagnosis, treatment, and related scenarios such as biomarkers, small cell lung cancer, and genomic mutations in non-small cell lung cancer (NSCLC).
Article Abstract
Lung cancer is the leading cause of cancer death in the US and globally. The mortality from lung cancer has been declining, due to a reduction in incidence and advances in treatment. Although recent success in developing targeted and immunotherapies for lung cancer has benefitted patients, it has also expanded the complexity of potential treatment options for health care providers. To aid in reducing such complexity, experts in oncology convened a conference (Bridging the Gaps in Lung Cancer) to identify current knowledge gaps and controversies in the diagnosis, treatment, and outcomes of various lung cancer scenarios, as described here. Such scenarios relate to biomarkers and testing in lung cancer, small cell lung cancer, EGFR mutations and targeted therapy in non-small cell lung cancer (NSCLC), early-stage NSCLC, KRAS/BRAF/MET and other genomic alterations in NSCLC, and immunotherapy in advanced NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/oncolo/oyae228 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!